Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002267158 | SCV002750847 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-06-25 | criteria provided, single submitter | clinical testing | The c.2893delA pathogenic mutation (also known as p.M965*), located in coding exon 10 of the BRCA2 gene, results from a deletion of one nucleotide at nucleotide position 2893. This changes the amino acid from a methionine to a stop codon within coding exon 10. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV003096056 | SCV003207360 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-03-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1696798). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Met965*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). |
Genomic Center, |
RCV002267158 | SCV002549105 | pathogenic | Hereditary cancer-predisposing syndrome | no assertion criteria provided | case-control |